Cas:1217501-04-6 [4-(cyclopropylmethylsulfinyl)phenyl]boronic acid manufacturer & supplier

Chemical Name:[4-(cyclopropylmethylsulfinyl)phenyl]boronic acid

CAS.NO:1217501-04-6

Synonyms:X1676;(4-((Cyclopropylmethyl)sulfinyl)phenyl)boronic acid

Molecular Formula:C₁₀H₁₃BO₃S

Molecular Weight:224.08400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:76.74000

Exact Mass:224.06800

LogP:0.74970

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like X1676 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-((Cyclopropylmethyl)sulfinyl)phenyl)boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4-((Cyclopropylmethyl)sulfinyl)phenyl)boronic acid Use and application,X1676 technical grade,usp/ep/jp grade.

Related News: Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. [4-(cyclopropylmethylsulfinyl)phenyl]boronic acid manufacturer Roche’s second anti-tau antibody UCB0107, partnered with UCB, is also slated to enter deeper testing this year. Tau had appeared to have fresh promise as a rival of sorts to amyloid. Tau theory goes that neurofibrillary tangles that form inside cells clog up the brain, and clearing this can help Alzheimer’s patients. [4-(cyclopropylmethylsulfinyl)phenyl]boronic acid supplier Three more patients have been confirmed infected with coronavirus in South Korea, bringing the country’s total to 15, the South Korean Centers for Disease Control and Prevention (KCDC) announced in a press release. [4-(cyclopropylmethylsulfinyl)phenyl]boronic acid vendor Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. [4-(cyclopropylmethylsulfinyl)phenyl]boronic acid factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.